Floatz logo

Arq 501

Cancer

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Phase 1/2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
65/ 100

Competitive context

1412 Active assets in the Cancer cohort.

Asset / SponsorPhaseRating
Nabiximols
Jazz Pharmaceuticals
Phase 3BBB
Inno-206
M.D. Anderson Cancer Center
Phase 2BB
Vitamin B6
M.D. Anderson Cancer Center
Phase 4BB
PROPOFOL
Hong Kong Children's Hospital
Phase 4BB
Rivoceranib
Jiangsu HengRui Medicine Co., Ltd.
Phase 4BB

View all 50 →

Same molecule, other indications

Arq 501 is also rated in:

adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →
pancreatic neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
hepatocellular carcinomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →